５Ｇ は体に非常に悪いというのは、前々から聞いて居ましたし、
なんとか設置はやめてほしいと思っていましたが、コロナウイルスは５Ｇ を導入した国ほど、コロナに罹って病気になっているようですよ。
恐ろしや。
特にイタリアの中にあるサンマリノ共和国は、世界で一番最初に５Ｇを導入した国であるらしいです。
以下の人の研究によると、
サンマリノは１０００人中１０人が罹患しているようです。
５Ｇ に住民が被ばく？していた期間が長いのが理由？
武漢も５Ｇ をスイッチオンしていましたし、イタリアも５Ｇ をせっきょくてきに取り入れていたようです。
これ↓
http://www.radiationdangers.com/5g/study-shows-direct-correlation-between-5g-networks-and-coronavirus-outbreaks-2/
２００５年のじてんで、トランプが服用しているクロロキンですが、
コロナウイルスに有効であると論文が出ていました。
６０年も前に開発され、１粒６０セントと安くて効くお薬が、もうからないとの事で、
排除されています。
https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69
Virology Journal volume 2, Article number: 69 (2005)
Severe acute respiratory syndrome (SARS) is caused by a newly discovered coronavirus (SARS-CoV). No effective prophylactic or post-exposure therapy is currently available.
We report, however, that chloroquine has strong antiviral effects on SARS-CoV infection of primate cells. These inhibitory effects are observed when the cells are treated with the drug either before or after exposure to the virus, suggesting both prophylactic and therapeutic advantage. In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations.
Chloroquine is effective in preventing the spread of SARS CoV in cell culture. Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection. In addition, the indirect immunofluorescence assay described herein represents a simple and rapid method for screening SARS-CoV antiviral compounds.
Severe acute respiratory syndrome (SARS) is an emerging disease that was first reported in Guangdong Province, China, in late 2002. The disease rapidly spread to at least 30 countries within months of its first appearance, and concerted worldwide efforts led to the identification of the etiological agent as SARS coronavirus (SARS-CoV), a novel member of the family Coronaviridae [1]. Complete genome sequencing of SARS-CoV [2, 3] confirmed that this pathogen is not closely related to any of the previously established coronavirus groups. Budding of the SARS-CoV occurs in the Golgi apparatus [4] and results in the incorporation of the envelope spike glycoprotein into the virion. The spike glycoprotein is a type I membrane protein that facilitates viral attachment to the cellular receptor and initiation of infection, and angiotensin-converting enzyme-2 (ACE2) has been identified as a functional cellular receptor of SARS-CoV [5]. We have recently shown that the processing of the spike protein was effected by furin-like convertases and that inhibition of this cleavage by a specific inhibitor abrogated cytopathicity and significantly reduced the virus titer of SARS-CoV [6].
Due to the severity of SARS-CoV infection, the potential for rapid spread of the disease, and the absence of proven effective and safe in vivo inhibitors of the virus, it is important to identify drugs that can effectively be used to treat or prevent potential SARS-CoV infections. Many novel therapeutic approaches have been evaluated in laboratory studies of SARS-CoV: notable among these approaches are those using siRNA [7], passive antibody transfer [8], DNA vaccination [9], vaccinia or parainfluenza virus expressing the spike protein [10, 11], interferons [12, 13], and monoclonal antibody to the S1-subunit of the spike glycoprotein that blocks receptor binding [14]. In this report, we describe the identification of chloroquine as an effective pre- and post-infection antiviral agent for SARS-CoV. Chloroquine, a 9-aminoquinoline that was identified in 1934, is a weak base that increases the pH of acidic vesicles. When added extracellularly, the non-protonated portion of chloroquine enters the cell, where it becomes protonated and concentrated in acidic, low-pH organelles, such as endosomes, Golgi vesicles, and lysosomes. Chloroquine can affect virus infection in many ways, and the antiviral effect depends in part on the extent to which the virus utilizes endosomes for entry. Chloroquine has been widely used to treat human diseases, such as malaria, amoebiosis, HIV, and autoimmune diseases, without significant detrimental side effects [15]. Together with data presented here, showing virus inhibition in cell culture by chloroquine doses compatible with patient treatment, these features suggest that further evaluation of chloroquine in animal models of SARS-CoV infection would be warranted as we progress toward finding effective antivirals for prevention or treatment of the disease.
In order to investigate if chloroquine might prevent SARS-CoV infection, permissive Vero E6 cells [1] were pretreated with various concentrations of chloroquine (0.1–10 μM) for 20–24 h prior to virus infection. Cells were then infected with SARS-CoV, and virus antigens were visualized by indirect immunofluorescence as described in Materials and Methods. Microscopic examination (Fig. 1A) of the control cells (untreated, infected) revealed extensive SARS-CoV-specific immunostaining of the monolayer. A dose-dependant decrease in virus antigen-positive cells was observed starting at 0.1 μM chloroquine, and concentrations of 10 μM completely abolished SARS-CoV infection. For quantitative purposes, we counted the number of cells stained positive from three random locations on a slide. The average number of positively stained control cells was scored as 100% and was compared with the number of positive cells observed under various chloroquine concentrations (Fig. 1B). Pretreatment with 0.1, 1, and 10 μM chloroquine reduced infectivity by 28%, 53%, and 100%, respectively. Reproducible results were obtained from three independent experiments. These data demonstrated that pretreatment of Vero E6 cells with chloroquine rendered these cells refractory to SARS-CoV infection.
世界中の人々が職業を失い、雇用がなくなり、家にいろ、、、と閉じ込められている中。
世界中の億万長者たちはコロナ騒動が始まってからたった、２３日で２８００億ドルも稼いでいるようです。
ビルゲイツのワクチンビジネスしかり、
彼はウイルスを巻いておいて、それを直すワクチンで、稼ぐのですから、マッチポンプもいいところですね。
これ
https://inequality.org/wp-content/uploads/2020/04/Billionaire-Bonanza-2020-April-21.pdf
税金を寄付するとか言って逃れてタックスヘイブンに移動させたり、
恐ろしい奴らです。
最近現れたミステリ－サ－クル。
コロナはマイクロソフトが作った？を表す？
わたしはニュ－ヨ－クにも仕事がら、（私の仕事はお葬式ア－ティスト）葬儀社の多くを知っていて、
私の作品である、ア－ト骨壺もニュ－ヨ－クのマンハッタンの葬儀社にて、販売をしている。
なので、情報が入りますが、
やはり、ニュ－ヨ－クでのコロナ患者の死亡人数は怪しいですね。
ニュ－ヨ－クの何人かの葬儀社が、コロナ感染のテストもしていないのにも関わらず、すべての死亡者をコロナ死にしているようです。
葬儀社が政府からそのようにするように、言われているようで、葬儀社の人たちがおかしいと訴えています。
やはり、ニュ－ヨ－クや、ほかのアメリカのコロナの死亡人数は正確ではなく、「やらせ」であると思います。
こちらをご覧あれ。
https://www.globalresearch.ca/funeral-directors-covid-19-epicenter-doubt-legitimacy-deaths-attributed-pandemic-fear-numbers-padded/5711447
